Thymic neuroendocrine tumors are rare and account for approximately 2% to 5% of all thymic tumors. Despite the suggestion of benign behavior implied by their name, thymic carcinoids have been noted to present a more aggressive biologic behavior than their counterparts in other sites. Because of the lack of data, adequate-sized prospective trials are required for validation, and the enrollment of patients with advanced disease into available clinical trials is encouraged.
Keywords: Chemotherapy; Neuroendocrine tumors; Outcome; Radiotherapy; Surgery; Thymus.
Copyright © 2014 Elsevier Inc. All rights reserved.